Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com

Protalix BioTherapeutics (NYSE:PLX) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday.

Separately, HC Wainwright lifted their price target on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday.

Protalix BioTherapeutics Stock Performance

NYSE PLX opened at $2.42 on Tuesday. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.54. The firm has a market capitalization of $178.18 million, a P/E ratio of -18.62 and a beta of 0.75. The stock has a 50-day simple moving average of $1.98 and a two-hundred day simple moving average of $1.41.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors have recently modified their holdings of the business. PFG Investments LLC acquired a new position in Protalix BioTherapeutics in the fourth quarter valued at $39,000. Sanctuary Advisors LLC purchased a new position in shares of Protalix BioTherapeutics during the 3rd quarter worth approximately $38,000. Virtu Financial LLC purchased a new position in shares of Protalix BioTherapeutics during the 3rd quarter worth approximately $44,000. XTX Topco Ltd purchased a new stake in Protalix BioTherapeutics in the 3rd quarter worth approximately $36,000. Finally, GSA Capital Partners LLP grew its stake in Protalix BioTherapeutics by 8.5% in the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after acquiring an additional 33,969 shares during the period. Institutional investors and hedge funds own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.